TICKERNERD
Menu
TPSTTPSTHealthcare · Biotechnology

TPST Stock Forecast: Tempest Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$0.37
−3.13% on the day

The 1 Wall Street analysts covering Tempest Therapeutics, Inc. hold a median 12-month price target of $7 — +1786.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 13 Nov 2026 — in the lower half.

Market cap
$7.7M
Ticker Nerd rank
49/ 100
Median analyst target
$7.00
Analysts covering
1
Revenue$0.0
Operating income−$5.3M
Net income−$5.2M
Free cash flow−$2.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
−45.5%
YTD
−87.1%
1Y
−95.8%
From 52W high
−96.0%
From 52W low
+2.8%
$0.36
$9.38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TPST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tempest Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
49/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Accruals
91
Growth
87
Issuance
54
Revisions
45
Value
28
Volatility
22
Momentum
16
Quality
15

Size (92): Smaller than most of the companies we track.

Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TPST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TPST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26TPSTHigh $7.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $7.00Median $7.00High $7.00

The green dot is the last close — the median target sits +1786.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Sept 2026HC Wainwright & Co.MaintainsBuy$11 → $7.00
22 Jan 2026HC Wainwright & Co.UpgradeBuy$11
22 Jan 2026HC Wainwright & Co.UpgradeBuy—
10 Apr 2025HC Wainwright & Co.DowngradeNeutral—
10 Apr 2025ScotiabankDowngradeSector Perform—
28 Mar 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025ScotiabankMaintainsSector Outperform—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024Piper SandlerMaintainsOverweight—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
21 June 2024Piper SandlerReiteratesOverweight—
20 June 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Mar 2024ScotiabankInitiatesSector Outperform—
13 Mar 2024ScotiabankInitiatesSector Outperform—
12 Mar 2024HC Wainwright & Co.MaintainsBuy—
8 Feb 2024JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TPST appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TPST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Tempest Therapeutics, Inc. returned −95.8% against +13.4% for the S&P 500, dividends included.

TPST vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26TPSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TPST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Tempest Therapeutics, Inc. (TPST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
−5.2×

Cheaper than 97% of US stocks

EV / EBITDA
−0.6×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−931.1%

Higher than 2% of US stocks

Return on assets
−79.4%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tempest Therapeutics, Inc. (TPST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tempest Therapeutics, Inc. has a market value of $7.7M and an enterprise value of $13.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$40.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$20.7M.

  • Shares outstanding: 16.0M.

  • Trailing P/E: −0.1×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tempest Therapeutics, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Nov 2026

Data provided by Twelve Data

Peers

TPST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TPSTTempest Therapeutics, Inc.$7.7M49
GTBPGT Biopharma, Inc.$7.7M14
CURXCuranex Pharmaceuticals, Inc.$7.5M8
SNGXSoligenix, Inc.$7.5M41
LGVNLongeveron, Inc.$7.9M48
VTGNVistagen Therapeutics, Inc.$8.0M29
CNSYCerenome, Inc.$7.2M14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tempest Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TPST news & analysis

Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Nov 2026positive

Tempest Therapeutics reported third-quarter 2026 financial results and a business update, including the exclusive license of Senlang’s CD7-targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903.

Why it matters — The update highlights a platform licensing development and initial Phase 1 results relevant to TPST’s pipeline.

Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

GlobeNewsWire · 11 Nov 2026positive

Tempest Therapeutics exercised its option to license Senlang’s CD7-targeted lentiviral in vivo CAR-T platform. The deal provides exclusive global rights outside China to the platform and a portfolio of in vivo CAR-T candidates, following initial Phase 1 results with Senlang’s lead BCMA/GPRC5D candidate.

Why it matters — The licensing decision expands the cell-therapy technologies and candidates available to Tempest outside China.

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

GlobeNewsWire · 23 Sept 2026positive

Tempest Therapeutics announced that Nancy Freda-Smith, a global finance leader, has been appointed to its board of directors and will serve as Chair of the Audit Committee. The appointment was announced on September 23, 2026.

Why it matters — Adding an experienced global finance executive to lead the Audit Committee strengthens Tempest's corporate governance and financial oversight at the board level.

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

Benzinga · 16 Sept 2026positive

Tempest Therapeutics shares traded sharply higher in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.

Why it matters — The option agreement with Hebei Senlang represents a new strategic partnership for Tempest that watchers of the company would want to track.

FAQ

Frequently asked questions about TPST stock

What is the TPST stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Tempest Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TPST stock a buy right now?

Of the 1 analysts covering Tempest Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tempest Therapeutics, Inc. 49 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TPST?

As at 13 Nov 2026, Tempest Therapeutics, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will TPST stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1786.8% from the last close, and Ticker Nerd's factor model ranks Tempest Therapeutics, Inc. 49 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TPST stock forecast for 2030?

No analyst covering Tempest Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TPST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.

How has TPST stock performed over the past year?

Tempest Therapeutics, Inc. returned -95.8% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tempest Therapeutics, Inc. do?

Tempest Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cancer therapies through targeted and immune-mediated mechanisms.

What is the latest news on TPST?

The most recent item we track (GlobeNewsWire, 13 Nov 2026): "Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update". Tempest Therapeutics reported third-quarter 2026 financial results and a business update, including the exclusive license of Senlang’s CD7-targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903.

Company

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cancer therapies through targeted and immune-mediated mechanisms. The company’s current pipeline centers on small molecule and cell therapy programs designed to address multiple oncology indications, including solid tumors and hematologic cancers. Its portfolio includes advanced investigational candidates that aim to modulate tumor biology, enhance anti-tumor immune responses, and broaden the reach of next-generation cell therapy approaches. Tempest Therapeutics also works with partners on certain clinical programs, reflecting a business model centered on drug development, clinical research, and translational oncology. Based in Brisbane, California, Tempest Therapeutics Inc. operates within the biopharmaceutical sector as a research-driven company advancing experimental treatments toward clinical evaluation.

CEO Dr. Matthew Angel Ph.D. · 4 employees · United States · https://www.tempesttx.com